Literature DB >> 1675587

High-frequency activation of single CD4+ and CD8+ T cells to proliferate and secrete cytokines using anti-receptor antibodies and IL-2(1).

E Maraskovsky1, M H Pech, A Kelso.   

Abstract

A high cloning efficiency single-cell culture system was developed to define the activation requirements of isolated CD4+ and CD8+ T cells to proliferate and secrete cytokines. T cells were triggered using solid-phase anti-CD3 and anti-CD4 or anti-CD8 antibodies plus rIL-2. Activation was measured by microscopic scoring of proliferation and by measurement of cytokine production using the cytokine-responsive cell lines FDC-P1, which responds to GM-CSF, IL-3, IFN-gamma and IL-4, and 32D clone 3 which responds to IL-3 only. Whilst anti-CD3 plus rIL-2 triggered only 4% of peripheral T cells to proliferate, anti-CD3 plus anti-CD8 mAb triggered about 40% of CD8+ T cells; 80% of the resultant clones secreted cytokine and 90% of these were IL-3+. Anti-CD3 plus anti-CD4 mAb triggered proliferation in about 20% of CD4+ T cells, of which 34% formed cytokine-producing clones with 47% of these secreting IL-3. In addition to responding at higher frequency, CD8+ T cells formed larger clones which produced higher levels of cytokines than CD4+ cells. Cell separation on the basis of Pgp-1 expression suggested that this culture system did not select for previously activated cells. Whereas Pgp-1+ T cells from keyhole limpet haemocyanin (KLH)-primed mice were enriched in KLH-specific cells, no significant differences were observed in the clonogenicity or cytokine-secreting capacity of Pgp-1+ and Pgp-1- T cells from normal mice.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1675587     DOI: 10.1093/intimm/3.3.255

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  1 in total

1.  Fas transduces activation signals in normal human T lymphocytes.

Authors:  M R Alderson; R J Armitage; E Maraskovsky; T W Tough; E Roux; K Schooley; F Ramsdell; D H Lynch
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.